Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.

Autor: Müller T; Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Gartenstr 1, 13088, Berlin, Germany. th.mueller@alexianer.de., Riederer P; Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany., Grünblatt E; Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland.; Neuroscience Center Zürich, University of Zürich and ETH Zürich, Zurich, Switzerland.; Zürich Center for Integrative Human Physiology, University of Zürich, Zurich, Switzerland.
Jazyk: angličtina
Zdroj: Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm (Vienna)] 2017 Jun; Vol. 124 (6), pp. 745-748. Date of Electronic Publication: 2017 Mar 15.
DOI: 10.1007/s00702-017-1705-z
Abstrakt: We determined monoamine oxidase-A (plasma) and -B (platelets) enzyme activity in chronic levodopa treated patients with Parkinson's disease after first time intake of an irreversible monoamine oxidase-B inhibitor. One patient received 10 mg selegiline and eleven patients took 1 mg rasagiline. A significant decrease of monoamine oxidase-B activity appeared 2 and 4 h following monoamine oxidase-B inhibitor intake in comparison to baseline. We confirm with this design, that rasagiline and selegiline inhibit monoamine oxidase-B but not monoamine oxidase-A after single dosing.
Databáze: MEDLINE
Externí odkaz: